Skip to content

Handai FMT study

Specified clinical trial for fecal microbiota transplantation and gut microbiota reconstruction in patients with refractory diarrhea

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs051220110
Enrollment
10
Registered
2022-10-26
Start date
2023-06-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory diarrhea

Interventions

Receive about 50 g or more of stool from the donor at screening test, dilute it 3 to 4 times with saline and mix. Centrifuge and filter, and finally consolidate to 200-300 ml. Store frozen until FMT

Sponsors

Shimizu Kentaro
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Study subject: (1) Aged 18 years or older at informed consent. (2) Patient with prolonged diarrhea more than 10 days despite of standard treatment for diarrhea, or who continue to have diarrhea without using antidiarrheal drugs. (3) Patient with dysbiosis in the gut assessed using stool smear. (4) Patient with written consent to participate in this study from the patient or his/her surrogate. Donor: (1) Aged 18-70 years (If possible, relatives of the study subject). (2) Patient without dysbiosis in the gut assessed using stool smear. (3) If the study subject has a food allergy, person who is possible not to consume the food for at least 5 days before stool collection. (4) Person with written consent from the person regarding the implementation of interview and various tests specified in this study and the provision of stool.

Exclusion criteria

Exclusion criteria: Study subject: (1) Patient with shock (blood lactate level 18 mg/dL or higher) or who using catecholamines. (2) Patient with severe immunodeficiency <500 / microL of neutrophils. (3) Patient who cannot expect a prognosis of 3 months or more even if diarrhea have subsided. (4) Patient who are judged by the investigator to be inappropriate as research subjects for other reasons. Donor: (1) Person suspected to have infection by interviewing and screening for blood and stool tests, or who have disease that should be excluded. Excluded diseases: inflammatory bowel disease, irritable bowel syndrome, chronic diarrhea, severe constipation, malignant tumor under treatment, autoimmune disease, severe obesity, Parkinson's disease, autism, depression, Creutzfeldt-Jakob's disease. For cytomegalovirus and EB virus, when the study subject is not infected, if the donor's screening test result is positive, it is non-eligible. (2) Parson who are judged by the investigator to be inappropriate as doner for other reasons

Design outcomes

Primary

MeasureTime frame
Adverse events

Secondary

MeasureTime frame
(1) Changes in stool shape (Bristol classification) (2) Changes in stool frequency (3) Changed in stool volume (4) Changes in gut microbiota (stool smear / culture, genome) (5) Changes in hematological tests and blood inflammation biomarkers

Contacts

Public ContactKentaro Shimizu

Osaka University Hospital

shimiken@hp-emerg.med.osaka-u.ac.jp+81-6-6879-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026